You do not need a diabetes diagnosis to get a GLP-1 in 2026. Wegovy\u00ae, Zepbound\u00ae, and Saxenda\u00ae are FDA-approved for obesity. Wegovy is also approved for cardiovascular risk reduction in patients with established CVD. Zepbound is approved for moderate-to-severe obstructive sleep apnea.<\/p>\n
This guide covers the FDA-approved non-diabetes paths, what eligibility looks like, what insurance covers, and how compounded options fit when brand coverage is not available. It pulls from FDA labeling, the registration trials (STEP, SURMOUNT, SELECT, SURMOUNT-OSA), and current clinical practice.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Three GLP-1s are FDA-approved for indications other than diabetes: Wegovy (semaglutide for obesity and CV risk reduction), Zepbound (tirzepatide for obesity and OSA), and Saxenda (liraglutide for obesity).<\/strong><\/p>\n Quick Answer: Wegovy is FDA-approved for obesity (BMI 30+ or 27+ with comorbidity)<\/p>\n Wegovy and Zepbound dominate in 2026 because they show the strongest weight loss in registration trials. STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% mean weight loss for Wegovy at 68 weeks. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% for Zepbound at 72 weeks. Saxenda’s SCALE trial showed 8.0% mean weight loss at 56 weeks.<\/p>\n Ozempic\u00ae and Mounjaro\u00ae are FDA-approved only for type 2 diabetes. Off-label prescribing for weight loss is legal but rarely covered by insurance and not the cleanest clinical path.<\/p>\n The obesity indication for Wegovy, Zepbound, and Saxenda requires BMI 30+ (obesity), or BMI 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, OSA, or established cardiovascular disease).<\/strong><\/p>\n This is the standard FDA criteria. Telehealth platforms apply the same criteria as in-person prescribers because the FDA labeling does not distinguish based on care setting.<\/p>\n You do not need a diabetes diagnosis. You do need either BMI 30+ alone or BMI 27+ with one qualifying comorbidity. Hypertension is the most common qualifier for BMI 27-29 patients, with hyperlipidemia second.<\/p>\n Zepbound was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.<\/strong> Eligibility requires a sleep study showing AHI 15+ and BMI 30+.<\/p>\n The SURMOUNT-OSA trial showed tirzepatide reduced AHI by roughly 27-30 events per hour over 52 weeks compared with placebo. This is clinically meaningful for many OSA patients.<\/p>\n The OSA indication unlocks insurance coverage in plans that exclude or restrict weight-loss drugs. Many commercial plans cover OSA treatments more readily than obesity treatments, and Zepbound for OSA can clear PA criteria that Zepbound for obesity cannot.<\/p>\n Wegovy was FDA-approved in March 2024 for cardiovascular risk reduction in adults with established CVD and obesity or overweight.<\/strong> Eligibility requires documented established CVD (prior MI, stroke, PAD, or coronary revascularization) plus BMI 27+.<\/p>\n The SELECT trial (Lincoff et al. 2023 NEJM) showed Wegovy 2.4 mg reduced major adverse cardiovascular events by 20% over a mean 39-month follow-up. Number needed to treat was 67.<\/p>\n The CV indication unlocks coverage in plans that exclude weight-loss drugs but cover cardiovascular medications. State Medicaid programs with categorical exclusions on obesity drugs sometimes approve Wegovy under the CV indication for eligible patients.<\/p>\n Commercial insurance coverage for obesity GLP-1s varies by plan.<\/strong> Plans with explicit obesity drug benefits cover Wegovy, Zepbound, and Saxenda with PA. Plans without obesity drug benefits exclude them entirely.<\/p>\n Medicare Part D does not cover any drug for obesity due to federal statutory exclusion (Medicare Modernization Act of 2003). The Wegovy CV indication created a workaround for Medicare patients with established CVD, allowing Part D coverage in some circumstances.<\/p>\n Medicaid coverage is state-by-state. 16 states covered Wegovy and 14 covered Zepbound for obesity as of Q1 2026. State exclusion states require alternate indications (CV for Wegovy, OSA for Zepbound) or cash-pay paths.<\/p>\n Brand retail prices: Wegovy roughly $1,350\/month, Zepbound roughly $1,060\/month, Saxenda roughly $1,350\/month.<\/strong> Direct-to-consumer programs offer lower self-pay rates for eligible patients.<\/p>\n NovoCare offers Wegovy at $499\/month for some uninsured patients meeting eligibility criteria. LillyDirect offers Zepbound single-dose vials at $349-549\/month for self-pay patients. Manufacturer copay cards for commercially insured patients can reduce out-of-pocket cost to $0-25\/month.<\/p>\n Compounded semaglutide and tirzepatide through legitimate 503A pharmacies run substantially below brand retail. TrimRx offers a free assessment quiz that screens eligibility and connects qualifying patients with licensed providers for a personalized treatment plan.<\/p>\n Key Takeaway: Wegovy is also FDA-approved for CV risk reduction in established CVD + BMI 27+<\/p>\n The intake covers height, weight, medical history, current medications, allergies, and goals.<\/strong> It also asks about comorbidities (hypertension, hyperlipidemia, OSA, CV history) that affect eligibility for BMI 27-29 patients.<\/p>\n You upload a government ID and recent labs (lipid panel, A1c or fasting glucose, CMP, TSH within the last 6-12 months). For the OSA indication, a recent sleep study supports the prescription.<\/p>\n A licensed prescriber reviews the intake within 24-72 hours. If you qualify, the prescription goes to a partnered pharmacy. The prescription can be for brand Wegovy, brand Zepbound, brand Saxenda, or compounded semaglutide or tirzepatide depending on platform and clinical fit.<\/p>\n You do not qualify under FDA labeling for any GLP-1.<\/strong> The minimum BMI is 27 (with comorbidity) for Wegovy, Zepbound, and Saxenda. BMI 30+ qualifies regardless of comorbidity.<\/p>\n For patients in the BMI 25-26 range with weight-related concerns, the clinical options are lifestyle intervention (the DPP showed lifestyle change reduces diabetes risk by 58%), non-GLP-1 weight medications like phentermine or naltrexone-bupropion, or addressing specific metabolic concerns directly.<\/p>\n Some telehealth platforms market GLP-1 access at lower BMI thresholds. These prescriptions are off-label or operate outside FDA labeling. They are technically legal under physician judgment but not clinically matched the trial populations and are rarely covered by insurance.<\/p>\n STEP 1 (Wilding et al.<\/strong> 2021 NEJM) enrolled 1,961 adults with BMI 30+ (or 27+ with comorbidity) without type 2 diabetes. The trial showed mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo. This is the foundational non-diabetic semaglutide weight-loss evidence.<\/p>\n SURMOUNT-1 (Jastreboff et al. 2022 NEJM) enrolled 2,539 non-diabetic adults with BMI 30+ (or 27+ with comorbidity). Mean weight loss at 72 weeks was 20.9% on tirzepatide 15 mg versus 3.1% on placebo. More than 50% of patients on 15 mg achieved 20%+ weight loss.<\/p>\n SURMOUNT-OSA enrolled non-diabetic patients with moderate-to-severe OSA and obesity. The trial showed clinically meaningful AHI reduction over 52 weeks. SELECT enrolled non-diabetic patients with established CVD and showed 20% MACE reduction.<\/p>\n The CV indication, approved March 2024, applies to adults with established cardiovascular disease and BMI 27+, regardless of whether they have diabetes.<\/strong> The indication shifts the clinical framing from weight loss to secondary prevention of cardiovascular events.<\/p>\n For insurance coverage, the CV indication can unlock approval in plans that exclude or restrict weight-loss drugs. Medicare Part D coverage of Wegovy is generally not allowed under the federal obesity exclusion, but the CV indication has created some workarounds for Medicare beneficiaries with established CVD.<\/p>\n Documenting the CV indication requires evidence of prior MI, stroke, PAD, or coronary revascularization. Recent imaging, hospital discharge summaries, or cardiologist notes all support the indication. Without documented established CVD, the CV indication does not apply.<\/p>\n Bottom line: Compounded semaglutide and tirzepatide are legal alternatives through 503A pharmacies<\/p>\n Off-label prescribing is legal but rarely covered by insurance. Wegovy is the FDA-approved semaglutide for obesity. Most prescribers redirect non-diabetic patients to Wegovy or compounded semaglutide.<\/p>\n FDA labeling does not require documented diet failure, but most insurance PA criteria do. Six months of documented lifestyle intervention is the typical insurance threshold for obesity GLP-1s.<\/p>\n Medicare Part D does not cover any drug for obesity. The Wegovy CV indication created a workaround for patients with established CVD, but obesity alone is not covered.<\/p>\n Prediabetes is not an FDA indication for any GLP-1. Some prescribers will use the BMI 27+ with comorbidity criteria if the patient also has hypertension or hyperlipidemia. The DPP showed lifestyle intervention reduces diabetes risk by 58% in prediabetes.<\/p>\n No. TrimRx provides compounded semaglutide and tirzepatide for patients qualifying under obesity indications (BMI 30+ or 27+ with comorbidity).<\/p>\n Compounded semaglutide or tirzepatide through legitimate 503A pharmacies is typically the lowest cash-pay cost. NovoCare ($499\/month for eligible patients) and LillyDirect ($349-549\/month) are the lowest brand options.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" You do not need a diabetes diagnosis to get a GLP-1 in 2026. Wegovy, Zepbound, and Saxenda are FDA-approved for obesity.<\/p>\n","protected":false},"author":11,"featured_media":90022,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"How to Get GLP-1 Without a Diabetes Diagnosis","_yoast_wpseo_metadesc":"You do not need a diabetes diagnosis to get a GLP-1 in 2026. Wegovy, Zepbound, and Saxenda are FDA-approved for obesity.","_yoast_wpseo_focuskw":"how get","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-90023","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90023"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90023\/revisions"}],"predecessor-version":[{"id":91563,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90023\/revisions\/91563"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90022"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Obesity Indication Require?<\/h2>\n
What Does the OSA Indication Unlock?<\/h2>\n
What Does the CV Indication Unlock?<\/h2>\n
What Does Insurance Cover for Non-diabetic GLP-1 Use?<\/h2>\n
What Does Cash-pay Look Like Without Insurance?<\/h2>\n
What Does the Online Intake Process Look Like?<\/h2>\n
What If I Have BMI 25-26?<\/h2>\n
What Does Each Registration Trial Show for Non-diabetic Populations?<\/h2>\n
What Does the Wegovy Cardiovascular Indication Mean in Practice?<\/h2>\n
FAQ<\/h2>\n
Can I Get Ozempic Without Diabetes?<\/h3>\n
Do I Need to Fail Other Diets First?<\/h3>\n
Will Medicare Cover GLP-1 for Obesity?<\/h3>\n
Can I Get a GLP-1 for Prediabetes?<\/h3>\n
Does TrimRx Require a Diabetes Diagnosis?<\/h3>\n
What Is the Cheapest Non-diabetic GLP-1 Path?<\/h3>\n